Suven Life Sciences gained on Tuesday after the company secured three product patents- one product patent from Australia, two product patents from Japan and one product patent from Hong Kong corresponding to the New Chemical Entity for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally," said Venkat Jasti, chief executive officer of Suven.

Shares of the company gained Rs 9.60, or 4.62%, to trade at Rs 217.25 at the BSE (11.27 a.m., Tuesday). The scrip has touched an intra-day high of Rs 225.70 and low of Rs 209.50 at the BSE.